EA8183
|
ECOG-ACRIN
|
A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA8184
|
ECOG-ACRIN
|
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
EA8185
|
ECOG-ACRIN
|
Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in clinical Stage 3, Node PosItive bladdeR cancEr (INSPIRE)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA8191
|
ECOG-ACRIN
|
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA8192
|
ECOG-ACRIN
|
A Phase II/III trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA8211
|
ECOG-ACRIN
|
Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA8212
|
ECOG-ACRIN
|
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA9131
|
ECOG-ACRIN
|
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
EA9152
|
ECOG-ACRIN
|
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA9161
|
Alliance
|
A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|